day 3 - toxicological considerations of vh2o2 sterilization residuals
Published 1 month ago • 155 plays • Length 1:00:03Download video MP4
Download video MP3
Similar videos
-
1:00:12
day 1 - vh2o2, sterilization considerations
-
59:18
day 2 - considerations for biocompatibility
-
1:53
best practices for vh2o2 sterilization
-
37:27
understanding ethylene oxide sterilization
-
56:41
after e&l: updates to the standard for toxicological risk assessment 10993-17
-
30:32
sterilization of your medical device
-
1:27
how to detox from food dyes
-
8:36
progress update: treating ibs with cellcore phase 3
-
48:04
thera03 ozone - kill viruses - safe breathable
-
2:22
biological indicators (bis) and chemical indicators (cis) working together for vh2o2 sterilization.
-
18:47
vh2o2 bio-decontamination interview: biosafety level 2 and level 3 laboratories
-
1:35
flt3 inhibitor maintenance after allo-sct for aml
-
2:46
update of the admiral trial: gilteritinib vs salvage chemotherapy prior to hsct in flt-3 mutated aml
-
0:39
do you know what vhp sterilization is?
-
59:07
testing requirements for a successful sterilization validation
-
3:55
ep0042, an inhibitor of flt3 & aurora kinases, in r/r aml and mds: insights from a phase i/iia trial
-
2:54
phase 3 select trial overview
-
1:36
kt-333: a first-in-class stat3 degrader
-
41:33
the new iso 10993-18 & updates to regulatory expectations regarding chemistry
-
59:21
sterilization methodologies & packaging integrity testing: updates, trends, & anticipated changes
-
1:46
exposure to sterilization